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4Drug-related infectious diseases in Europe
Population at risk: people who inject drugs 
While evidence from drug treatment centres suggests that 
the prevalence of injecting drug use is declining in the 
European Union, Norway and Turkey, this group is at high risk 
of contracting blood-borne viruses and other infections. As 
of 2018, the estimated national prevalence of injecting drug 
use ranged from less than 1 per 1 000 in Cyprus, the 
Netherlands and Spain to more than 5 per 1 000 in Czechia, 
Estonia and Latvia. While heroin remains overall the most 
commonly injected drug in Europe, stimulants such as 
cocaine, amphetamines and synthetic cathinones are also 
injected, and predominate in some countries.
The high burden of viral hepatitis
Hepatitis C virus (HCV) is the most prevalent blood-borne 
virus infection among people who inject drugs, with many 
countries reporting the prevalence of HCV antibodies (a 
marker of having been infected by the virus) among this 
group in excess of 50 %. While the prevalence of hepatitis 
B virus (HBV) surface antigen (a marker of being currently 
infected) among people who inject drugs is under 5 % in 
most countries, it is still much higher than in the general 
population, despite the availability of an effective and safe 
vaccine. Individuals who remain chronically infected are at 
risk of cirrhosis and cancer, and can transmit the virus to 
others when sharing injecting materials that have been in 
contact with their blood.
Overall decline in HIV cases but outbreaks linked to 
stimulant injecting still detected
While people who inject drugs now account for a smaller 
proportion of new human immunodeficiency virus (HIV) 
cases in the European Union, Norway and Turkey (less 
than 5 % of all new diagnoses in 2017), HIV infections 
linked to injecting drug use are being diagnosed late, 
and local HIV outbreaks among people who inject drugs 
are still being documented in Europe (Germany, 
Lithuania and the United Kingdom). The newly 
documented HIV outbreak in Bavaria included in this 
report adds to the list of other recent HIV outbreaks 
linked to an increase in stimulant injection: Dublin 
2014-15 (synthetic cathinones, alpha-PVP), Luxembourg 
2014-17 (cocaine) and Glasgow 2015 (cocaine).
Key interventions for elimination: prevention, testing 
and treatment
Ending the HIV/AIDS epidemic and combating viral 
hepatitis is part of the United Nation’s 2030 Agenda for 
Sustainable Development. Achieving this goal will 
require scaling-up the harm reduction services offered 
to people who inject drugs and access to diagnosis and 
effective treatment (antiretroviral therapy and direct-
acting antiviral treatment). Despite the well-documented 
cost-effectiveness of prevention measures, such as 
needle and syringe programmes and opioid substitution 
treatment, their national coverage, as monitored by the 
European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), is still sub-optimal in many 
European countries. While available data on the HIV 
cascade of care for people who inject drugs are 
encouraging, there are still barriers to testing and 
providing this group access to direct-acting 
antiviral treatment for hepatitis C.
At a glance
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I Introduction
This report provides an update on infectious diseases 
related to drug use in Europe for the period up to February 
2019. It provides an overview of the most recent infectious 
disease surveillance data, outbreak investigations, and 
prevention and control measures among people who inject 
drugs in Europe, collected through the EMCDDA drug-
related infectious diseases (DRID) network.
The first section describes the population at risk: the 
number of injectors and the main injecting practices. The 
second section presents the latest data related to newly 
diagnosed cases and prevalence estimates of HCV, HBV 
and HIV infections in Europe. The third section provides an 
update and a follow-up on recently documented infectious 
disease outbreaks among people who inject drugs in 
Europe. The fourth section presents the European 
overview of harm reduction intervention coverage, testing 
and treatment. The final section outlines the public health 
messages of the latest guidance for prison settings in the 
context of infectious disease prevention and control in 
prisons in three EU Member States.
I Population at risk
I Prevalence of injecting drug use in Europe
The prevalence of injecting drug use, defined as the 
proportion of the population aged 15-64 who have injected 
illicit drugs in the last year, is measured through indirect 
statistical methods such as capture-recapture (King et al., 
2014) or treatment multiplier (Larney et al., 2017) studies 
and comes with a high degree of uncertainty. In studies 
conducted from 2015 onwards, the estimated prevalence 
of injecting drug use ranged from less than 1 per 1 000 in 
Cyprus, the Netherlands and Spain to more than 5 per 
1 000 in Czechia, Estonia and Latvia (Figure 1).
I Stimulant injecting is established
While heroin and other opioids remain overall the most 
commonly injected drugs in Europe, stimulants are also 
injected, and predominate in certain countries, as reflected 
by data from drug services in Czechia, France, Hungary and 
Latvia. The European Syringe Collection and Analysis 
Project Enterprise (ESCAPE) also obtained information on 
injected substances by analysing in laboratories the residual 
content of used syringes in six cities in 2017 (Amsterdam, 
Budapest, Glasgow, Helsinki, Lausanne and Paris) 
(EMCDDA, 2019a). A high proportion of syringes were found 
to contain stimulants in all six cities, which may indicate 
a high prevalence of stimulant use among people who inject 
drugs. This has potentially important implications, since 
stimulant injecting has been associated with higher-risk 
injecting practices and a higher prevalence of unsafe sex 
than opioid injecting has (Cavazos-Rehg et al., 2009).
FIGURE 1
Estimated prevalence of injecting drug use in the European Union and Norway, with indication of most commonly injected 
drug, 2015-17 
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I  Risk factor for transmission: sharing of needles/syringes
In recent national or local biological and behavioural 
surveillance studies, the proportion of people who inject 
drugs reporting sharing used needles/syringes in the last 4 
weeks was 47 % in Bulgaria (National Centre for 
Addictions, 2017), 44 % in Romania (National Antidrug 
Agency, 2016) and 39 % in Hungary (Dudás et al., 2015). 
Under the treatment demand indicator protocol, those 
entering specialised drug treatment who report drug 
injecting are asked about their sharing of used needles/
syringes in the last 4 weeks. The data available for 17 
countries in 2017 suggest that, in eight countries, more 
than 10 % of all treatment entrants who report injecting 
drugs have recently shared a needle or syringe (Figure 2). 
It is important to note that people reporting drug injection 
on treatment entry might not be representative of all 
people who inject drugs, and those not in contact with 
services may have higher levels of drug use and injecting.
I  Viral hepatitis among people who inject drugs in Europe
I  Injecting drug use as main risk factor for newly diagnosed cases of HCV infection
In the European Union and Norway, 30 778 cases of 
hepatitis C virus (HCV) infection were notified in 2017. 
Among the cases for which information on the 
transmission mode is available, injecting drug use was 
reported as the likely cause for 40 % (178/445) of acute 
cases and 55 % of chronic cases (1 305/2 363) (ECDC, 
2018b). For hepatitis B virus (HBV) infection, an estimated 
11 % of the 2 788 acute cases reported in 2017 in the 
European Union and Norway were linked to injecting drug 
use (ECDC, 2018a).
FIGURE 2
Self-reported sharing of needles or syringes among people entering drug treatment reporting injecting drugs, 2017 
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I  High prevalence of HCV antibodies among people who inject drugs
The prevalence of antibodies to HCV (anti-HCV) among 
people who inject drugs — indicating present or past 
infection, either cleared or treated — is estimated from 
seroprevalence studies or routine diagnostic tests offered 
in drug treatment centres or by low-threshold services. In 
2016-17, anti-HCV prevalence among people who inject 
drugs varied from 15 % to 82 % (EMCDDA, 2019b). In eight 
out of the 14 countries with national data, more than half 
of people who inject drugs have been infected with HCV 
(Figure 3). Among countries with national trend data for 
the period 2011-17, declining anti-HCV prevalence among 
injecting drug users was reported in four countries, while 
three reported an increase.
I  Prevalence of HBV infection still high despite effective vaccine
Among drug users, HBV infection is less common than 
HCV infection, but is still higher than in the general 
population, despite the availability of an effective vaccine, 
which is included in recommended vaccination schedules 
in most EU countries (ECDC, 2018c). For this virus, the 
presence of the HBV surface antigen (HBsAg) indicates 
a current infection, which may be recent or chronic. In the 
five countries with national data for 2016-17, between 
1.4 % and 9.4 % of injecting drug users were estimated to 
be currently infected with HBV (EMCDDA, 2019b).
I  HIV among people who inject drugs in Europe
I  Overall decline in newly notified cases of HIV infection linked to injecting drug use
In the European Union, Norway and Turkey, the total 
number of newly notified cases of human 
immunodeficiency virus (HIV) infection attributed to 
injecting drug use has been declining overall since the 
2011-12 outbreaks in Greece and Romania (Figure 4). In 
2017, there were a total of 940 newly notified case of HIV 
infection attributed to injecting drug use (Germany not 
included), corresponding to 4.6 % of all new cases with 
information on the mode of transmission (ECDC and WHO, 
2018). Imputing the German notifications for 2017 with 
their 2016 level (127), the European total for notifications 
of HIV infection linked to injecting drug use would have 
been expected to reach 1 067 in 2017. In 2017, the most 
common transmission modes remained sex between men 
(51 % of new cases with information on transmission 
mode) and heterosexual transmission (44 % of new cases 
with information on transmission mode).
FIGURE 3
HCV antibody prevalence (percent) among people who inject drugs: results from seroprevalence studies and diagnostic 
tests, with national and subnational coverage, 2016-17 
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While people who inject drugs now account for a smaller 
proportion of newly notified cases of HIV infection overall, 
challenges remain. First, HIV infections linked to injecting 
drug use are still being diagnosed late. Where information 
was available, 51 % of newly notified cases of HIV infection 
attributed to injecting drug use in the European Union in 
2017 were diagnosed several years after infection had 
occurred — with CD4 counts below 350 cells/mm3. Late 
diagnosis delays antiretroviral treatment, and increases the 
risk of ill health, death and HIV transmission. In 2017, a total 
of 375 diagnoses of acquired immunodeficiency syndrome 
(AIDS) in people infected with HIV through injecting drug 
use were reported in the European Union, Norway and 
Turkey. Second, local HIV outbreaks among people who 
inject drugs are still being documented (see section 
‘Outbreaks of infectious diseases among drug users’ below).
I  Prevalence of HIV infection among people who inject drugs
Despite the reduction in the proportion of newly diagnosed 
cases of HIV infection attributable to injecting drug use 
relative to other transmission modes in Europe, the risk of 
HIV infection among people who inject drugs remains high 
and the prevalence of infection among this group exceeds 
by far the prevalence in the general population. Recent 
estimates (2016-17) of HIV prevalence among people who 
inject drugs are available for 19 countries. Figures for HIV 
prevalence of more than 10 % have been reported among 
populations of people of who inject drugs in Estonia, 
Greece, Italy, Latvia, Poland, Portugal, Romania and Spain 
(Figure 5). Figures of 5 % to 10 % for HIV prevalence were 
reported by national studies carried out in Austria, Greece, 
Latvia and Luxembourg, and by a subnational study 
conducted in Sofia, Bulgaria. The results of earlier HIV 
prevalence studies (before 2016) can be accessed in the 
online Statistical Bulletin (EMCDDA, 2019b).
I  Outbreaks of infectious diseases among drug users
Local outbreaks of HIV infection among people who inject 
drugs are still being documented. Other outbreaks of 
public health importance among this group include 
outbreaks of bacterial infections.
I  HIV outbreak linked to synthetic cathinones in Munich, Germany
An increase in the number of HIV cases among people who 
inject drugs was detected in the Bavaria region with 18 
cases reported in 2015 and 35 in 2016, compared with 
only eight cases reported in 2014 (Fiedler et al., 2018). 
Most cases were reported from Munich. Sequencing 
analysis and recency tests were performed on dried serum 
spots sent to the Robert Koch Institute (available for 60 % 
of newly diagnosed and notified HIV cases). The proportion 
of infections acquired in the last 5 months was highest for 
cases diagnosed in 2016 (35 %), indicating that 
transmission peaked in that year. Subtyping of samples 
from Bavaria and phylogenetic analysis showed that the 
increase was driven by a cluster of HIV-1 subtype 
C infections. The analyses also showed that most people 
infected with HIV were co-infected with HCV. Synthetic 
cathinones (such as alpha-PVP/PV8) were frequently 
detected in the dried serum spots analysed. Information 
from low-threshold services in the area also suggested 
that there might be an association between the increase in 
HIV cases and group consumption of stimulant new 
psychoactive substances.
FIGURE 4
Notifications of cases of HIV infection attributed to injecting 
drug use in the European Union, Norway and Turkey, 2008-17
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I  HIV outbreak linked to injecting drug use in prison, Lithuania
In Lithuania, the number of newly diagnosed cases of HIV 
infection related to injecting drug use reached 136 in 2017 
(62 % of all new HIV cases), corresponding to an incidence 
of 48 per million inhabitants, the highest in the European 
Union. This increase seems to be largely associated with 
transmission in prison settings, where new cases 
continued to be reported in 2018. In 2017, there were 
97 newly diagnosed cases of HIV infection in prisons in the 
country; 55 % of these cases were reported from Alytus 
prison (1 015 detainees in 2017) and the majority have 
been linked to injecting drug use (Figure 6). While 
information on HIV transmission and HIV testing are 
available for people in prison in Lithuania and coverage of 
HIV treatment has been increasing, access to effective 
measures to prevent the transmission of blood-borne 
diseases, as well as condom distribution, remains limited. 
Receiving opioid substitution treatment in prison is 
possible for only those who had started treatment prior to 
imprisonment.
FIGURE 5
HIV antibody prevalence (percent) among people who inject drugs: results from seroprevalence studies and diagnostic tests, 
with national and subnational coverage, 2016-17 
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FIGURE 6
Newly diagnosed HIV cases reported from prisons 
in Lithuania, 2012-18 
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FIGURE 7
Invasive group A streptococcus biological samples 
received by Public Health England Respiratory and 
Vaccine Preventable Bacteria Reference Unit with risk 
factor of injecting drug use recorded, 2007-17 
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I  Update on the HIV outbreak in Glasgow, United Kingdom
From November 2014 to January 2018, a total of 119 new 
HIV cases among homeless people who inject drugs were 
notified in Glasgow. This is the largest cluster of people 
who inject drugs infected with HIV that has been 
documented in the United Kingdom since the 1980s 
(Ragonnet-Cronin et al., 2018). Common characteristics 
of cases include a history of incarceration, homelessness 
and high rates of HCV infection indicative of needle 
sharing. The outbreak has also been strongly linked to 
injecting cocaine (McAuley et al., 2019). Surveillance data 
from needle and syringe programmes using dried blood 
testing and data from syringe residues in 2017 indicate 
that injecting cocaine use with or without heroin has 
become more common among people who inject drugs in 
Glasgow (EMCDDA, 2019a). Another important feature of 
this outbreak is that harm reduction services (including 
the provision of injecting equipment and opioid 
substitution treatment) were available before and during 
the outbreak: needle and syringe programmes in Glasgow 
distribute over 1 million syringes per year. Increasing 
access for vulnerable homeless populations to 
prevention, harm reduction and HIV treatment has 
therefore been a priority for local public health services, 
for instance by linking infectious disease and homeless 
addictions teams in the city.
I  Increasing reports of injecting-related bacterial infections in the United Kingdom
Bacterial infections among people who inject drugs are 
often related to poor general hygiene and unsafe injection 
practices. They are associated with a significant burden of 
disease and have a substantial impact on health services. 
In England, the mandatory enhanced surveillance of 
methicillin-sensitive Staphylococcus aureus (MSSA) and 
methicillin-resistant Staphylococcus aureus (MRSA) 
collects information on risk factors (Public Health England 
et al., 2018). In 2017, of those with risk factor information 
available, 14 % (410/2 877) of MSSA and 11 % (40/348) of 
MRSA infections were associated with injecting drug use, 
indicating an increase over the last 6 years. Invasive group 
A streptococcus (iGAS) isolates are sent to the Public 
Health England Respiratory and Vaccine Preventable 
Bacteria Reference Unit. The number and proportion of 
iGAS infections associated with injecting drug use has 
increased since 2013 (Figure 7). A prolonged outbreak of 
iGAS type emm/66 with local clusters of infection among 
people who inject drugs has been described. Of 10 early 
cases for which there is information on drug use, eight 
occurred in people who had reported injecting, mainly 
heroin (eight) and crack (six). Four people reported sharing 
spoons/mixing containers and filters, but not needles 
(Bundle et al., 2017). Cases of iGAS type emm/66 
infections continue to occur and more than 100 cases 
have been recorded to date. Intervention measures in the 
towns affected include targeted communications 
campaigns to raise awareness about infection control. 
Data on hospitalisation in England also show an upwards 
trend in the number of episodes of serious infection 
among people who inject drugs since 2012 (Lewer et al., 
2017). The authors of the study that reviewed these 
hospital data (Lewer et al., 2017) listed a number of factors 
potentially associated with this increase, including an 
ageing cohort of people who inject drugs and the injection 
of new psychoactive substances.
Cases of wound botulism continue to occur among people 
who inject drugs in the United Kingdom, probably due to 
the environmental contamination of heroin with botulism 
spores. In Scotland there have been four confirmed and 
one probable case of would botulism investigated since 
February 2019. All five affected individuals are known to 
have injected drugs. One of the five has died; cause of 
death is under investigation. The source of the infection is 
believed to be heroin contaminated with Clostridium 
botulinum spores. In the autumn of 2018, there was also 
a cluster of four cases of wound botulism in people who 
11
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inject drugs in England, with reported onset dates between 
19 October and 11 November 2018. Two cases were 
confirmed and two were probable. Three cases were 
reported from the South of England and one from the 
Midlands; all were known injecting heroin users.
I Stimulant injecting and outbreak risk
The injection of stimulants has been associated with 
higher HIV risk as a result of higher levels of unsafe sex 
and unsafe injecting (Cavazos-Rehg et al., 2009). The 
newly documented HIV outbreak among people who inject 
drugs in Germany adds to the list of other recent HIV 
outbreaks linked to an increase in stimulant injection: 
Dublin 2014-15 (synthetic cathinones, alpha-PVP; Giese et 
al., 2015), Luxembourg 2014-17 (cocaine; McAuley et al., 
2019) and Glasgow 2015 (cocaine; Arendt et al., 2019). 
Injecting of stimulants is being described in Europe 
through different sources. In a recent trendspotter study 
conducted by the EMCDDA (EMCDDA, 2018), an increase 
in cocaine powder injecting, alone or in combination with 
heroin, was reported in drug consumption rooms in France, 
Germany, Luxembourg, Spain and Switzerland. The 
trendspotter study also highlighted an increasing trend in 
injecting cocaine base (crack), either alone or as a cheaper 
alternative to traditional speedball preparations. In 2017, 
the ESCAPE network, set up by the EMCDDA to obtain 
information on injected substances by analysing the 
residual content of used syringes, found that a high 
proportion of syringes contained stimulants in all six 
participating cities, which may indicate a high prevalence 
of stimulant use among people who inject drugs 
(EMCDDA, 2019a).
I  Prevention and treatment of drug-related infectious diseases in Europe
There is an effective vaccine against HBV. Moreover, when 
implemented in combination, at a high level of coverage, 
needle exchange programmes and opioid substitution 
treatment are cost-effective interventions that prevent 
blood-borne infections among people who inject drugs (Platt 
et al., 2017). Prevention and harm reduction measures are 
therefore key interventions aimed at ending the HIV/AIDS 
epidemic and eliminating viral hepatitis as a public health 
threat among people who inject drugs, since they prevent new 
infections and also provide an opportunity to reach out to 
high-risk populations for testing and linking them to care.
Sub-optimal needle and syringe programme 
coverage persists
National-level data on the coverage of needle and syringe 
programmes (calculated as the number of syringes 
distributed from specialised and publicly subsidised 
programmes annually per person who injects drugs) are 
available for 16 countries, with only four of these (Estonia, 
Finland, Luxembourg and Norway) providing a level of 
coverage that is above the 2020 target of 200 syringes per 
injecting drug user (Figure 8).
FIGURE 8
Coverage of specialised syringe programmes: estimated number of syringes provided per person who injects drugs in 
2017, European Union and Norway
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FIGURE 9
Coverage of opioid substitution treatment (percentage of estimated high-risk opioid users receiving treatment) in 2017 or 
most recent year and in 2007/08
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Opioid substitution treatment coverage is improving 
in some European countries
The coverage of opioid substitution treatment, calculated as 
the percentage of estimated high-risk opioid users receiving 
treatment, is estimated to be at or above the 2020 World 
Health Organization (WHO) target of 40 % in 11 of the 18 EU 
countries for which estimates of the population of high-risk 
opioid users are available (Figure 9). In the European Union 
as a whole, about half of the high-risk opioid users receive 
substitution treatment. In those countries for which data for 
2007 or 2008 are available for comparison, there was 
generally an increase in coverage between 2007 or 2008 
and 2017. Levels of provision, however, remain low in some 
countries. These data indicate a need to improve the 
coverage of substitution treatment and needle exchange 
interventions in many European countries.
Identifying barriers to HCV testing among people 
who inject drugs
To eliminate viral hepatitis as a public health threat, the 
WHO target aims for 50 % of people who are chronically 
infected with viral hepatitis to be diagnosed by 2020, and 
75 % of eligible patients to be receiving treatment. Yet 
many infections still go undiagnosed and untreated among 
people who inject drugs. In some of the injecting drug use 
prevalence studies described earlier, investigators also 
looked at HCV tests done in the previous 12 months. In 
recent European studies, the proportion of people who 
inject drugs who have been tested in the last 12 months 
(excluding those who know their positive status) ranged 
from 7 % in Romania (National Antidrug Agency, 2016) to 
66 % in France (Cadet-Taïrou et al., 2018). As part of the 
EMCDDA treatment demand indicator (TDI), drug 
treatment entrants who report injecting drugs are asked 
about previous HCV tests. Only in 4 of the 14 countries 
providing recent data did the majority of treatment 
entrants questioned report having been tested for HCV in 
the last 12 months (Figure 10).
In May 2018, the EMCDDA launched a 3-year initiative with 
the purpose of promoting HCV testing among people who 
inject drugs in drug treatment settings. The EMCDDA HCV 
testing initiative represents both an operationalisation of 
a central EMCDDA public health priority as well as the 
implementation of a dynamic intervention model 
presented in the European guide on health and social 
responses to drug problems (EMCDDA, 2017).
The EMCDDA pilot project in this area comprises three 
modules: Module 1 examines barriers to HCV testing; 
Module 2 is a compendium of models of care regarding 
HCV testing and referral to care; and Module 3 focuses on 
materials that support the promotion of HCV testing in 
drug treatment settings. Through this project, the 
EMCDDA aims to assist EU Member States in their efforts 
to improve national practices in the hepatitis C field by 
supporting an analysis of the national situation and by 
providing high-quality materials for training activities for 
those working in the field.
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Access to direct-acting antiviral treatment for people 
who inject drugs
Direct-acting antivirals are an effective treatment option 
for people chronically infected with HCV. The goal of 
therapy is to cure HCV infection in order to prevent 
complications and mortality, to improve quality of life, 
remove stigma and prevent onward transmission of HCV. 
The WHO recommends offering treatment to all individuals 
diagnosed with HCV infection who are 12 years of age or 
older (with the exception of pregnant women), irrespective 
of disease stage (WHO, 2018). The guidelines also stress 
that treating people who inject drugs along with provision 
of harm reduction interventions is cost-effective. The 
beneficial impact of treatment for the infected individual 
and the indirect impact of reduced transmission in the 
community (treatment as prevention) make testing and 
linkage to treatment a core component of the elimination 
strategy. However, in spring 2018, in 8 of the 11 EU 
Member States without an HCV policy, clinical guidelines 
still restricted access to HCV treatment for people who 
inject drugs (Nielsen, 2018), and 5 EU countries restricted 
direct-acting antiviral reimbursement for patients with drug 
or alcohol dependencies (Marshall et al., 2018).
Cascade of care for HCV infection in Luxembourg
In Luxembourg, the Institute of Health and the Centre for 
Infectious Diseases undertook a study among 295 drug 
users recruited at the drug consumption room and three 
harm reduction agencies between November 2015 and 
December 2017. The aims of the study were to describe 
the risk-taking practices of drug users, to test participants 
for infectious agents (HCV, HBV, HIV, syphilis), viral load 
and liver markers, to carry out fibroscanning and to link 
them to care, in order to document the cascade of care for 
HCV infection and identify barriers.
Of the 295 participants, 71 % were male and 26 % did not 
have a social security number. The mean age was 38.7 
years. Eighty-two percent were current injectors, half of 
them reporting injecting at least once a day. Cocaine use, 
often associated with heroin use, was reported by 59 %. 
Anti-HCV prevalence was 72 %. Among these, 62 % had 
a detectable HCV viral load. Among users with 
a detectable HCV viral load, 31 % had fibrosis stage F2 or 
greater. Half of these patients (54 %) returned to the 
hospital and received direct-acting antiviral treatment, and 
82 % achieved a sustained viral response 12 weeks after 
the end of treatment.
Based on this cascade of care (Figure 11), a series of 
barriers was identified. First, while there is no health 
insurance restriction for current injectors’ access to 
direct-acting antiviral treatment, clinicians still prioritise 
the treatment of those with more advanced stage fibrosis. 
Second, it usually took 2-3 weeks for patients to get the 
results of the RNA test, which measures viral load. Only 
half of patients with a diagnosis of advanced fibrosis went 
FIGURE 10
Self-reported history of HCV testing among people entering drug treatment reporting injecting drugs 
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to their hospital appointment for treatment initiation. One 
of the recommendations following this study was to 
provide the result of the viral load and the eligibility for 
treatment on the same day, and to offer support with 
hospital appointments. Moreover, direct-acting antiviral 
treatment is now directly provided at the drug 
consumption room and at other harm reduction centres by 
a nurse, who is responsible for treatment initiation and 
follow-up of patients. Direct-acting antiviral treatment for 
people who inject drugs is also available in prisons and in 
a homeless shelter, and can be prescribed by medical 
doctors prescribing opioid substitution treatment.
Reaching the WHO targets for HCV among people 
who inject drugs
While observational studies measuring the impact of 
interventions targeting people who inject drugs are scarce, 
mathematical modelling can provide some insights into 
how far we are from reaching the WHO targets for viral 
hepatitis elimination and what remains to be done. 
A recent study looked at baseline levels of HCV 
seroprevalence, opioid substitution treatment and needle 
and syringe programme coverage, and direct-acting 
antiviral HCV treatment rates among people who inject 
drugs in 11 European sites (countries and cities) in 2016 
(Fraser et al., 2018a). Using a dynamic HCV transmission 
model among people who inject drugs, it assessed the 
impact by 2026 of different strategies in terms of 
prevalence and incidence. These projections outlined 
some important messages. First, they suggest that opioid 
substitution treatment and needle and syringe 
programmes alone would not be enough to reach the 
elimination targets: the combination of opioid substitution 
treatment, needle and syringe programmes and HCV 
treatment would be required. Second, while not sufficient 
by themselves, scaling-up opioid substitution treatment 
and needle and syringe programmes for people who inject 
drugs would increase the impact of HCV treatment as 
a prevention strategy, and would reduce the number of 
HCV treatments needed to achieve the targets. Third, 
a majority of sites still require a substantial increase in 
HCV treatment coverage in order to reduce incidence to 
2 per 100 person-years. The team has also undertaken 
other modelling that shows the importance of treating 
re-infections and of continuing treatment even after 
elimination targets have been achieved (Fraser et al., 
2018b).
FIGURE 11
Continuum of care for HCV infection in an outreach 
programme for injecting drug users in Luxembourg, 
2015-17 
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Monitoring progress towards the elimination of viral hepatitis among people who inject 
drugs — the EMCDDA elimination barometer
Following the global health strategy on viral hepatitis 
(WHO, 2016), WHO Europe produced an action plan for 
the health sector response to viral hepatitis in the WHO 
European region (WHO, 2017). The goal is to achieve 
reductions in the incidence of chronic HBV and HCV 
infections of 30 % by 2020 and 90 % by 2030, and 
reductions in the mortality from chronic HBV and HCV 
infections of 10 % by 2020 and 65 % by 2030. The 
EMCDDA is working with its expert network on drug-
related infectious diseases (DRID network) on a dedicated 
list of indicators — the elimination barometer — to identify 
data gaps and assess progress towards the elimination of 
HBV and HCV infection among people who inject drugs. 
The five building blocks of the elimination barometer are 
(1) context and needs (epidemic pattern), (2) inputs 
(policy), (3) prevention, (4) testing and linkage to care, and 
(5) impact. Each building block includes quantitative and/
or qualitative indicators with a corresponding target. The 
elimination barometer will be available on the EMCDDA 
website in 2019.
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Reaching the United Nations targets for HIV among 
people who inject drugs
In 2014, the Joint United Nations Programme on HIV/AIDS 
(UNAIDS) set the 90-90-90 targets, whereby 90 % of all 
people infected with HIV would be diagnosed, 90 % of 
those diagnosed would be receiving treatment and 90 % of 
those receiving treatment would achieve viral suppression 
by 2020 (Sidibé et al., 2016). These UNAIDS fast-track 
targets translate into viral suppression in 73 % of all people 
living with HIV, reducing onward transmission (‘treatment 
as prevention’). Mathematical modelling suggests that 
reaching these targets by 2020 will enable the world to 
meet the goal of ending the HIV/AIDS epidemic by 2030, 
as part of the 2030 agenda for sustainable development.
In 2018, four EU countries were able to report data on all 
four stages of the cascade of care for people who inject 
drugs (ECDC, 2019). Pooling the data from Austria, France, 
Luxembourg and the United Kingdom, 94 % of the 
estimated 15 697 people who inject drugs living with HIV 
were diagnosed, 93 % of those diagnosed were receiving 
antiretroviral therapy and 95 % of those on antiretroviral 
therapy were virally suppressed. However, looking at 
individual countries (Figure 12), only France (which 
reported 12 100 people who inject drugs living with HIV in 
2018) reached all three targets.
I  Drug-related infectious diseases in prison settings
I EU overview
On 1 September 2016, the rate of imprisonment in the 
European Union, Norway and Turkey was estimated at 129 
per 100 000 inhabitants, equivalent to 766 000 people in 
prison on that day (Council of Europe, 2016). Prison 
settings can be high-risk environments for contracting 
blood-borne infections. A significant proportion of people 
in prison have a history of drug use, and a strong 
association has been found between prison history and 
FIGURE 12
Continuum of HIV care for people who inject drugs in four EU countries, shown as percentage of estimated people who 
inject drugs living with HIV in 2018
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blood-borne virus prevalence in people who inject drugs. 
Reviews of prison studies from EU countries found 
prevalence estimates ranging from 0.3 % to 25.2 % for HBV 
infection, from 4.3 % to 86.3 % for HCV antibodies, and 
from 0.2 % to 15.8 % for HIV infection (EMCDDA and 
ECDC, 2018). Poor infrastructure, overcrowding, 
inadequate healthcare facilities and delayed diagnosis are 
risk factors for infections in prison settings, where much of 
the burden of blood-borne virus infection is linked to 
a history of injecting drug use. Opioid substitution 
treatment in prison was reported to be available by 29 of 
the 30 countries monitored by the EMCDDA, and HBV 
vaccination schemes for prisoners were reported by 16 
countries. While testing for one or more blood-borne 
viruses was reported to be provided in prison systems by 
26 countries in 2016, treatment of HBV and HCV infection 
was reported to be available in prison in 7 and 11 of the EU 
Member States, respectively (EMCDDA, 2017).
I  HCV testing strategy among newly incarcerated prisoners in Estonia
There were an estimated 2 670 prisoners in Estonia on 
1 September 2016 (Council of Europe, 2016), corresponding 
to an incarceration rate of 196 per 100 000 inhabitants, 
higher than the European average (see above). Since 2014, 
Estonian prison health authorities have been implementing 
a new testing strategy whereby HCV tests are offered to all 
newly incarcerated prisoners. The implementation of the 
project ‘Improvement of prevention and treatment of 
infectious diseases in Estonian prisons’, which focuses on 
testing, treatment and infrastructure building, is considered 
a milestone in HCV diagnosis and care in Estonian prisons 
(Kivimets et al., 2018).
Between 2014 and 2015, a total of 1 845 newly 
incarcerated prisoners were tested for HCV (Kivimets et al., 
2018). The average age of prisoners tested was 35 years 
and 94 % were male; 58 % had used illicit drugs, 28 % were 
tattooed and 69 % had been previously incarcerated. The 
prevalence of HCV antibodies was 56 % and the 
prevalence of HIV infection was 26 %. When comparing 
prisoners testing positive for HCV infection with those 
testing negative and after adjusting for potential 
confounders, a history of drug use was the factor most 
strongly associated with HCV seropositivity. The new 
screening strategy allowed 271 new cases of HCV 
infection to be identified among prisoners. As a condition 
for initiating HCV treatment (with pegylated interferon and 
ribavirin), programme-based addiction treatment was 
required for patients with a history of drug use. Twenty-five 
prisoners received it: 15 (60 %) were cured, 4 (16 %) 
relapsed and 3 (12 %) were unresponsive. These results 
did not differ from the treatment outcomes reported from 
a hospital setting in Estonia.
I  Programme ‘HCV, HBV, HIV and TB in a prison in Greece’
Since October 2017, the programme ‘HCV, HBV, HIV and 
TB in a prison in Greece’ has been running in the largest 
prison in the country, Korydallos Prison (including the 
prison hospital of Korydallos), located in Athens. Guided by 
the principles of intervention research, the programme is 
designed to screen detainees with a drug use background 
for blood-borne infections and TB and link those in need to 
specialised care. The research component of the 
programme includes the collection and analysis of 
serological and behavioural data (using the European 
Questionnaire on Drug Use among Prisoners). Based on 
data collected between October 2017 and March 2018, 
from 200 prisoners with a history of injecting drug use 
(61 % of 328 detainees approached), 56 % were confirmed 
HIV-positive and 84 % were anti-HCV-positive (Haikalis et 
al., 2018). More than half (57 %) of the entire sample had 
chronic hepatitis C and were eligible to receive treatment 
with direct-acting antivirals (that is, they had CHC/
HIV-coinfection and/or liver stiffness greater than 7.0 kPa) 
(Sypsa et al., 2018). The high proportion of HIV-infected 
prisoners is due to the 2011 outbreak of HIV infection that 
occurred in Athens among people who inject drugs and to 
the fact that the majority of HIV-positive prisoners are 
detained in the prison hospital of Korydallos.
I Screening and linking to care in a French prison
In France, the 2010 Précavar study (Semaille et al., 2011) 
estimated that 10 % of the prison population was receiving 
opioid substitution treatment and that a third of people 
who inject drugs in prisons have shared injecting material 
at least once. In 2018, the Villeneuve-les-Maguelone 
prison had a total of 950 inmates (570 places). Within 24 
hours of their arrival, new prisoners are received by a nurse 
and are given a consultation with a medical doctor of the 
health unit. A blood test for HIV, hepatitis A virus, HBV, HCV 
and syphilis, and a pulmonary X-ray are systematically 
offered to all new inmates (uptake is 70 %). Since 2015, 
direct-acting antiviral treatment against HCV has been fully 
reimbursed by the French national health insurance 
system, and, since 2017, treatment of chronic HCV 
infection has been offered to patients regardless of 
fibrosis stage. At Villeneuve-les-Maguelone, treatment is 
given once a day under the supervision of a nurse. In 2017, 
among the 1 100 people entering prison tested, 85 (7.5 %) 
tested positive for HCV antibodies. Among these 
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individuals, 27 (32 %) were diagnosed with chronic HCV 
infections. All chronically infected inmates were offered 
direct-acting antiviral treatment and 25 (93 %) started 
treatment. The completion rate in prison was 90 % and 
a sustained virologic response was achieved in 23 (92 %) 
of those that received treatment. When an inmate is 
released before the end of treatment, he or she is given the 
rest of the course of treatment to take at home.
In 2010, the prevalence of chronic HCV infections among 
new inmates at Villeneuve-les-Maguelone was 8.6 % 
(73/852). Seven years later, in 2017, the prevalence had 
decreased to 2.5 % (27/1 100), suggesting that the 
treatment strategy may be having some impact.
I Prison guidance
In 2018, the European Centre for Disease Prevention and 
Control (ECDC) and the EMCDDA published an evidence-
based guidance aimed at supporting the planning and 
implementation of effective programmes to prevent and 
control blood-borne viruses in prison settings in the 
European region. Based on a series of systematic reviews of 
the scientific literature and expert opinion, the document 
provides the following evidence-based recommendations 
(ECDC and EMCDDA, 2018; Tavoschi et al., 2019):
 § offer a comprehensive package of preventive measures 
to people in prison (including opioid substitution 
treatment and provision of clean drug injection 
equipment) that meet the same national standards as 
those recommended for community settings;
 § offer HBV vaccination to people in prison with unknown 
or negative serology;
 § actively offer blood-borne virus testing to all people in 
prison upon admission and throughout their time in 
prison;
 § offer appropriate treatment to individuals diagnosed 
with HIV, HBV or HCV infection in prison settings, in line 
with the guidelines applied in the community and 
meeting the same provision standards as in the 
community;
 § actively support and ensure continuity of care between 
prison and community.
This report provides an update on surveillance and 
monitoring data from the EMCDDA drug-related 
infectious diseases (DRID) expert network based on 
reports presented during the expert meeting held in 
Lisbon in September 2018 and data provided to the 
EMCDDA until February 2019. The next DRID expert 
meeting will be held in October 2019 at the EMCDDA 
headquarters in Lisbon.
I  Updates on European joint actions and projects
I  Joint action HA-REACT: work package on testing and linkage to care (WP4)
The objective of this work package was to improve early 
diagnosis of HIV, viral hepatitis and tuberculosis, as well as 
linkage to care for people who inject drugs. The German 
NGO Deutsche AIDS-Hilfe coordinated the work package 
activities, collaborating with partners from other countries. 
Based on a risk assessment by the ECDC and the 
EMCDDA, Hungary, Latvia and Lithuania were chosen as 
focus countries of the joint action, and experts from 
Hungary and Latvia participated in WP4 by developing 
a model for early diagnosis and linkage to care for low-
threshold services working with people who inject drugs. 
Further WP4 activities included workshops on testing and 
linkage to care for social workers and peers, and working in 
low-threshold settings; and the development of a training 
manual and e-learning tool on testing as well as of 
recommendations for a gender-specific approach for 
testing services. For more information, see: www.hareact.
eu/en/about-ha-react.
I  HepCare Europe: bridging the gap in the treatment of HCV infection
The HepCare Europe project, an EU-funded collaboration 
project between five institutions across four EU Member 
States (Ireland, Romania, Spain and the United Kingdom), 
developed, implemented and evaluated a number of 
innovative approaches to improving the testing and 
treatment of HCV infection among vulnerable populations 
(homeless people, prisoners, people who inject drugs) and 
implemented various training activities. As of May 2018, 55 
primary care sites had received HCV training, more than 
500 healthcare professionals had been trained and a total 
of 2 079 people had been screened for HCV infection 
under this project. For more information, see: www.ucd.ie/
medicine/hepcare/
I  SPHERE-C: development of a European prevalence survey for HCV
To address the gaps and heterogeneity in existing HCV 
prevalence data across EU countries, the ECDC-funded 
SPHERE-C project developed an evidence-based protocol 
for undertaking HCV prevalence surveys in the general 
population. The protocol covers three survey designs that 
all rely on probability-based sampling. Each of the study 
designs was piloted in three EU countries during 2018. The 
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results will feed into the revision of the SPHERE-C final 
study protocol. For more information, see: https://www.rki.
de/DE/Content/InfAZ/H/HepatitisC/SPHERE-C.html
I Glossary of terms and abbreviations
Acute viral hepatitis infection: discrete-onset clinical 
manifestations of a recent infection with a hepatitis virus.
AIDS: acquired immunodeficiency syndrome.
Anti-HCV: antibodies to hepatitis C virus (HCV), which can 
be detected in the blood usually within 2 or 3 months of 
HCV infection exposure. People who clear the infection 
naturally or who are successfully treated will still test 
positive for antibodies to HCV. Antibodies can be detected 
with serological assays, including rapid diagnostic tests 
and laboratory-based immunoassays (such as enzyme 
immunoassays).
Cascade of care: the cascade encompasses prevention, 
treatment and care interventions. The term ‘cascade’ 
emphasises that a sequence of services is needed to 
achieve the desired impact. The cascade concept also 
informs tracking of patients from one service to the next, 
and highlights the gradual attrition of coverage of the 
eligible population over the steps of the sequence 
(WHO, 2016).
Chronic viral hepatitis infection: chronic inflammation of 
the liver that results from a chronic infection with 
a hepatitis virus.
Current injector: a person who has injected drugs in the last 
12 months, not according to medical prescription. Some 
studies can restrict their study population to a subset of 
current injectors with shorter recall period, for example, 
injectors who have reported injecting in the last 4 weeks.
Direct-acting antiviral: an effective treatment against HCV 
infection.
ESCAPE: European Syringe Collection and Analysis 
Project Enterprise.
Ever-injector: a person who has injected drugs in the 
course of their life. Ever-injectors include current injectors 
and those who do not inject anymore.
HBV: hepatitis B virus.
HCV: hepatitis C virus.
HCV RNA: HCV viral genome that can be detected and 
quantified in serum by nucleic acid testing. Detection of 
HCV RNA indicates recent or chronic infections.
Hepatitis B surface antigen (HBsAg): HBV envelope 
protein detectable in the blood with rapid diagnostic tests 
or laboratory-based immunoassay in recent and chronic 
HBV infection.
HIV: human immunodeficiency virus.
iGAS: invasive group A streptococcus.
People who inject drugs: those who inject drugs not 
according to medical prescription.
Prevalence: the proportion of individuals in a defined 
population with a specific infection or disease (or specific 
characteristic) at a certain point in time.
Prevalence estimates from diagnostic tests: positivity rate 
(proportion of people testing positive among all people 
tested in a given period) obtained from routine diagnostic 
tests carried out by health services. Prone to more biases 
than seroprevalence studies.
Recent viral hepatitis infection: a newly acquired infection, 
regardless of whether it is symptomatic or asymptomatic. 
A small subset of people may develop acute hepatitis. Some 
new infections can evolve into chronic infections while 
others evolve towards spontaneous clearance of the virus.
Seroprevalence studies (SP): epidemiological studies 
specifically designed to obtain information on the 
prevalence of HIV/HBV/HCV biomarkers. A seroprevalence 
study is based on a protocol with well-defined target 
population, inclusion criteria, sampling frame, sampling 
method and sample size.
UNAIDS: Joint United Nations Programme on HIV/AIDS.
WHO: World Health Organization.
I References
I  Arendt, V., Guillorit, L., Origer, A., Sauvageot, N., Vaillant, M., 
Fischer, A., Goedertz, H., et al. (2019), ‘Injection of cocaine is 
associated with a recent HIV outbreak in people who inject drugs 
in Luxembourg’, PLOS ONE 14(5), pp. e0215570.
I  Bundle, N., Bubba, L., Coelho, J., Kwiatkowska, R., Cloke, R., King, S., 
Rajan-Iyer, J., et al. (2017), ‘Ongoing outbreak of invasive and 
non-invasive disease due to group A Streptococcus (GAS) type 
emm 66 among homeless and people who inject drugs in England 
and Wales, January to December 2016’, Eurosurveillance 22(3), 
doi:10.2807/1560-7917.ES.2017.22.3.30446.
I  Cadet-Taïrou, A., Lermenier-Jeannet, A. and Gautier, S. (2018), 
Profils et pratiques des usagers de drogues rencontrés dans les 
CAARUD en 2015, OFDT, Saint-Denis La Plaine.
I  Cavazos-Rehg, P. A., Spitznagel, E. L., Schootman, M., Strickland, 
J. R., Afful, S. E., Cottler, L. B. and Bierut, L. J. (2009), ‘Risky 
sexual behaviors and sexually transmitted diseases: 
a comparison study of cocaine-dependent individuals in 
treatment versus a community-matched sample’, AIDS Patient 
Care and STDs 23(9), pp. 727-734.
I  Council of Europe (2016), Council of Europe Annual Penal 
Statistics, http://wp.unil.ch/space/space-i/prison-stock-on-1st-
january/prison-stock-on-01-jan-2015-2016/ (accessed on 
11 January 2018).
19
Update from the EMCDDA expert network I June 2019
I  Devaux, C., Fischer, A., Da Silva, N., Goedertz, H., Karier, R., 
Menster, M., Ambroset, G., et al. (2018), ‘Continuum of HCV care 
in an outreach program for intravenous drug users in 
Luxembourg’, presentation, EMCDDA drug-related infectious 
diseases expert meeting, 24-25 September, Lisbon.
I  Dudás, M., Rusvai, E., Tarján, A., Minárovits, J., Takács, M. and 
Csohán, Á. (2015), ‘Official report on prevalence of infections 
related to injecting drug use in 2015’, unpublished report.
I  ECDC (European Centre for Disease Prevention and Control) 
(2018a), Annual epidemiological report for 2016: Hepatitis B, 
Surveillance Report, Publications Office of the European Union, 
Luxembourg (https://ecdc.europa.eu/en/publications-data/
hepatitis-b-annual-epidemiological-report-2016).
I  ECDC (2018b), Annual epidemiological report for 2016: Hepatitis 
C, Surveillance Report, Publications Office of the European 
Union (https://ecdc.europa.eu/en/publications-data/hepatitis-
c-annual-epidemiological-report-2016).
I  ECDC (2018c), Vaccine schedules in all countries of the 
European Union, https://vaccine-schedule.ecdc.europa.eu/ 
(accessed on 11 January 2018).
I  ECDC (2019), Continuum of HIV care — Monitoring 
implementation of the Dublin Declaration on Partnership to Fight 
HIV/AIDS in Europe and Central Asia: 2018 progress report, 
Special Report, Publications Office of the European Union, 
Luxembourg (https://ecdc.europa.eu/en/publications-
data?f%5B0%5D=publication_series%3A1520).
I  ECDC and EMCDDA (2018), Public health guidance on 
prevention and control of blood-borne viruses in prison settings, 
ECDC and EMCDDA Scientific Advice, Publications Office of the 
European Union (https://ecdc.europa.eu/en/publications-data/
public-health-guidance-prevention-control-bloodborne-viruses-
prison-settings).
I  ECDC and WHO (2018), HIV/AIDS surveillance in Europe 
2018-2017 data, Publications Office of the European Union, 
Luxembourg (https://ecdc.europa.eu/en/publications-data/
hivaids-surveillance-europe-2017-2016-data).
I  EMCDDA (European Monitoring Centre for Drugs and Drug 
Addiction) (2017), Health and social responses to drug problems: 
a European guide, Publications Office of the European Union, 
Luxembourg (http://www.emcdda.europa.eu/publications/
manuals/health-and-social-responses-to-drug-problems-a-
european-guide_en).
I  EMCDDA (2018), Recent changes in Europe’s cocaine market: 
results from an EMCDDA trendspotter study, Rapid 
Communication, Publications Office of the European Union, 
Luxembourg (http://www.emcdda.europa.eu/publications/
rapid-communications/recent-changes-in-europes-cocaine-
market_en).
I  EMCDDA (2019a), Drugs in syringes from six European cities: 
results from the ESCAPE project 2017, Rapid Communication, 
Publications Office of the European Union, Luxembourg (http://
www.emcdda.europa.eu/publications/rapid-communications/
syringe-residues-study-2017).
I  EMCDDA (2019b), Statistical Bulletin: Drug-related infectious 
diseases, http://www.emcdda.europa.eu/data/stats2019/drid.
I  EMCDDA and ECDC (2018), Guidance in Brief: Prevention and 
control of blood-borne viruses in prison settings, Joint 
Publications, Publications Office of the European Union, 
Luxembourg (http://www.emcdda.europa.eu/publications/
joint-publications/ecdc/brief-guidance-blood-borne-viruses-in-
prison_en).
I  Fiedler, S., Hauser, A., Grumann, C., Machnowska, P., Altmann, B., 
Hanke, K., Hofmann, A., et al. (2018), ‘Nachweis und Analyse 
eines HIV-1 Ausbruchs unter Drogengebrauchenden im Raum 
München mit Hilfe der molekularen Surveillance’, presentation, 
19 Interdisziplinärer Kongress für Suchtmedizin, Munich.
I  Fraser, H., Martin, N. K., Brummer-Korvenkontio, H., Carrieri, P., 
Dalgard, O., Dillon, J., Goldberg, D., et al. (2018a), ‘Model 
projections on the impact of HCV treatment in the prevention of 
HCV transmission among people who inject drugs in Europe’, 
Journal of Hepatology 68(3), pp. 402-411.
I  Fraser, H., Zibbell, J., Hoerger, T., Hariri, S., Vellozzi, C., Martin, 
N. K., Kral, A. H., et al. (2018b), ‘Scaling-up HCV prevention and 
treatment interventions in rural United States-model projections 
for tackling an increasing epidemic: Prevention and treatment for 
HCV in rural United States’, Addiction 113(1), pp. 173-182.
I  Giese, C., Igoe, D., Gibbons, Z., Hurley, C., Stokes, S., McNamara, S., 
Ennis, O., et al. (2015), ‘Injection of new psychoactive substance 
snow blow associated with recently acquired HIV infections among 
homeless people who inject drugs in Dublin, Ireland, 2015’, 
Eurosurveillance 20(40), doi:10.2807/1560-7917.
ES.2015.20.40.30036.
I  Haikalis et al. (2018), ‘Prevalence of HCV infection among 
imprisoned population with a history of injection drug use’, 
presentation, 6th Panhellenic Scientific Meeting ‘AIDS 
&Hepatitis’, September 2018, Athens.
I  King, R., Bird, S. M., Overstall, A. M., Hay, G. and Hutchinson, S. J. 
(2014), ‘Estimating prevalence of injecting drug users and 
associated heroin-related death rates in England by using 
regional data and incorporating prior information’, Journal of the 
Royal Statistical Society: Series A (Statistics in Society) 177(1), 
pp. 209-236.
I  Kivimets, K., Uusküla, A., Lazarus, J. V. and Ott, K. (2018), 
‘Hepatitis C seropositivity among newly incarcerated prisoners 
in Estonia: data analysis of electronic health records from 2014 
to 2015’, BMC Infectious Diseases 18(1), doi:10.1186/s12879-
018-3242-2.
I  Larney, S., Hickman, M., Guy, R., Grebely, J., Dore, G. J., Gray, 
R. T., Day, C. A., et al. (2017), ‘Estimating the number of people 
who inject drugs in Australia’, BMC Public Health 17(1), 
doi:10.1186/s12889-017-4785-7.
I  Lewer, D., Harris, M. and Hope, V. (2017), ‘Opiate injection-
associated skin, soft tissue, and vascular infections, England, 
UK, 1997-2016’, Emerging Infectious Diseases 23(8), pp. 1400-
1403.
20
Drug-related infectious diseases in Europe
I  Marshall, A. D., Cunningham, E. B., Nielsen, S., Aghemo, A., Alho, 
H., Backmund, M., Bruggmann, P., et al. (2018), ‘Restrictions for 
reimbursement of interferon-free direct-acting antiviral drugs for 
HCV infection in Europe’, The Lancet Gastroenterology & 
Hepatology 3(2), pp. 125-133.
I  McAuley, A., Palmateer, N., Goldberg, D., Trayner, K., Shepherd, S. 
and Gunson, R. (2019), ‘Re-emergence of injecting drug 
use-related HIV despite a comprehensive harm reduction 
environment: a cross sectional analysis’, The Lancet HIV, 
doi:10.1016/S2352-3018(19)30036-0.
I  National Antidrug Agency (2016), ‘Behavioural surveillance 
survey among IDUs from Bucharest-2015’ (http://www.ana.gov.
ro/stire283.php).
I  National Centre for Addictions (2017), ‘Annual Report of the 
National Centre for Addictions 2017’.
I  Nielsen, S. (2018), ‘HCV policies landscape in Europe’ (available 
at http://www.emcdda.europa.eu/document-library).
I  Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., 
Jordan, A., et al. (2017), ‘Needle syringe programmes and opioid 
substitution therapy for preventing hepatitis C transmission in 
people who inject drugs’, Cochrane Database of Systematic 
Reviews, doi:10.1002/14651858.CD012021.pub2.
I  Public Health England, Health Protection Scotland, Public Health 
Wales and Public Health Agency Northern Ireland (2018), 
Shooting up: infections among people who inject drugs in the 
UK, 2017, Public Health England, London (available at https://
www.gov.uk/government/publications).
I  Ragonnet-Cronin, M., Jackson, C., Bradley-Stewart, A., Aitken, C., 
McAuley, A., Palmateer, N., Gunson, R., et al. (2018), ‘Recent and 
rapid transmission of HIV among people who inject drugs in 
Scotland revealed through phylogenetic analysis’, Journal of 
Infectious Diseases 217(12), pp. 1875-1882.
I  Semaille, C., Le Strat, Y., Chiron, E., Barbier, C., Cate, L. and 
Chemlal, K. (2011), ‘La prévalence de l’hépatite C chez les 
personnes détenues en France : Enquête Prévacar 2010’, 
presentation, 69è journées scientifiques de l’association pour 
l’étude du foie, Paris (http://opac.invs.sante.fr/index.
php?lvl=notice_display&id=10327).
I  Sidibé, M., Loures, L. and Samb, B. (2016), ‘The UNAIDS 
90-90-90 target: a clear choice for ending AIDS and for 
sustainable health and development’, Journal of the International 
AIDS Society 19:21133 doi:10.7448/IAS.19.1.21133.
I  Sypsa, V., Kalamitsis, G., Papatheodoridis, G., Georgoulas, S., 
Psichogiou, M., Paraskevis, D., Dragassaki, M., et al. (2018), 
‘A pilot program of screening and linkage to care for hepatitis C in 
a Greek prison’, presentation, 7th International Symposium on 
Hepatitis Care in Substance Users (INSHU), Cascais, Portugal.
I  Tavoschi, L., O’Moore, É. and Hedrich, D. (2019), ‘Challenges and 
opportunities for the management of infectious diseases in 
Europes’ prisons: evidence-based guidance’, The Lancet 
Infectious Diseases pp. S1473309918307564.
I  WHO (2016), Global health sector strategy on viral hepatitis 
2016-2021: towards ending viral hepatitis, WHO, Geneva (http://
www.who.int/iris/handle/10665/246177).
I  WHO (2017), Action plan for the health sector response to viral 
hepatitis in the WHO European region, WHO Regional Office for 
Europe, Copenhagen (available at http://www.euro.who.int).
I  WHO (2018), Guidelines for the care and treatment of persons 
diagnosed with chronic hepatitis C virus infection, World Health 
Organization, Geneva.
I Acknowledgements
EMCDDA: Thomas Seyler, Eleni Kalamara, Isabelle 
Giraudon, Dagmar Hedrich and André Noor.
DRID network: Irene Schmutterer, Luk Van Baelen, Violeta 
Bogdanova, Marko Markus, Ioanna Yasemi, Barbara 
Janikova, Gry St-Martin, Kristel Kivimets, Henrikki 
Brummer-Korvenkontio, Anne-Claire Brisacier, Ruth 
Zimmerman, Anastasios Fotiou, Anna Tarjan, Sean Millar, 
Barbara Suligoi, Anda Kivite, Ieva Vaitkevičiūtė, Carole 
Devaux, Christine Marchand-Agius, Esther Croes, Rikard 
Rykkvin, Karolina Zakrzewska, Domingos Duran, Zuzana 
Kamendy, Maja Milavec, Elena Alvarez, Maria Axelsson and 
Vivian Hope.
External experts: Hannah Fraser, Alexandra Gurinova, Ida 
Sperle, Jack Lambert, Katherine Sinka, Stine Nielsen and 
Fadi Meroueh.
ECDC: Erika Duffell, Anastasia Pharris, Lina Nerlander, 
Teymur Noori and Andrew Amato.
WHO Europe: Antons Mozalevskis.
GETTING IN TOUCH WITH THE EU
In person
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Direct information centres. You can find the address of the 
centre nearest you at: http://europa.eu/contact
On the phone or by e-mail
Europe Direct is a service that answers your questions about 
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•  by freephone: 00 800 6 7 8 9 10 11  
(certain operators may charge for these calls) 
•  at the following standard number: +32 22999696 or
•  by electronic mail via: http://europa.eu/contact
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Online
Information about the European Union in all the official 
languages of the EU is available on the Europa website at: 
http://europa.eu  
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You can download or order free and priced EU publications 
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Multiple copies of free publications may be obtained by 
contacting Europe Direct or your local information centre  
(see http://europa.eu/contact)
EU law and related documents
For access to legal information from the EU, including all 
EU law since 1951 in all the official language versions, go to 
EUR-Lex at: http://eur-lex.europa.eu
Open data from the EU
The EU Open Data Portal (http://data.europa.eu/euodp/en/data)  
provides access to datasets from the EU. Data can be 
downloaded and reused for free, both for commercial and  
non-commercial purposes.
About this publication
Rapid communications bring you the latest findings 
and discussions in key areas in the drugs field. This 
report presents an overview of infectious diseases 
among people who inject drugs in Europe, both in the 
community and in prison settings, covering disease 
surveillance, outbreak investigations, and prevention 
and control, for the period up to the end of February 
2019. The report describes the population at risk, in 
terms of the number of injectors and the main injecting 
practices, presenting the latest data on incidence and 
prevalence of drug-related hepatitis C and B virus and 
HIV infections, as well as recent outbreaks, among 
people who inject drugs in Europe. This is accompanied 
by an overview of harm reduction intervention coverage, 
testing and treatment.
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For over 20 years, it has been collecting, analysing and 
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